fep blue glp-1 coverage 2026 Medicare Bridge Program Explained: Medications for Weight Loss Bad News re: BCBS FEP
Description
With respect to major adverse cardiovascular events, the use of the GLP-1 receptor agonist-SGLT-2 inhibitor combination in female patients was associated with a lower hazard ratio (0.39, 0.22 to 0.71) compared with male patients (0.96, 0.66 to 1.40
Ameer B, Weintraub M
B and Ros clinical obesity lead Dr
Dersjant-Li, Y., Awati, A., Schulze, H., & Partridge, G
The addition of effective medications such as Ozempic to a medical weight loss program provides significantly more success within a shorter timeline
